Exanta Superiority To Warfarin Could Reduce Safety Concerns – Cmte.
Executive Summary
AstraZeneca's Exanta should demonstrate more definitive superiority to Bristol-Myers Squibb's Coumadin (warfarin) prior to approval, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed
You may also be interested in...
FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority
The pivotal issue remaining for FDA's review of Boehringer Ingelheim's Pradaxa (dabigatran) is whether it will clear both the 110 mg and 150 mg doses and how it can craft labeling to guide appropriate use toward the higher dose, which seems likely to gain a superiority claim over warfarin.
AstraZeneca Rethinking Blockbuster Model After Exanta “Not Approvable”
FDA's "not approvable" decision for AstraZeneca's Exanta highlights the increasing difficulty of developing drugs with blockbuster potential while satisfying strict regulatory standards
AstraZeneca Rethinking Blockbuster Model After Exanta “Not Approvable”
FDA's "not approvable" decision for AstraZeneca's Exanta highlights the increasing difficulty of developing drugs with blockbuster potential while satisfying strict regulatory standards